Share Buyback

Zydus Lifesciences Announces ₹1,100 Crore Share Buyback at ₹1,260 Per Share Through Tender Offer Route

NSE

zyduslife

BSE

532321

Zydus Lifesciences has launched a buyback of up to 87.30 lakh equity shares at ₹1,260 per share for an aggregate consideration not exceeding ₹1,100 crore. The buyback will be executed through the tender offer route and represents approximately 0.87% of the company’s paid-up equity share capital. The offer opens on June 4, 2026 and closes on June 10, 2026. The initiative is intended to return capital to shareholders while optimizing the capital structure.

PRICE-SENSITIVE TRIGGER

Event: Launch of share buyback through tender offer route.

Type: Share Buyback / Capital Return

Impact: Positive

Immediate Effect: Eligible shareholders as of the record date can tender shares at a buyback price of ₹1,260 per share, providing an exit opportunity at a premium and improving capital allocation efficiency.

Key Metrics:

Buyback Size: ₹1,100 crore
Buyback Price: ₹1,260 per equity share
Maximum Shares to be Bought Back: 87,30,158 equity shares
Equity Share Capital Covered: 0.87%
Record Date: May 29, 2026
Buyback Opening Date: June 4, 2026
Buyback Closing Date: June 10, 2026
Settlement Completion: June 17, 2026

Highlight:

Buyback Size: ₹1,100 crore through tender offer route at ₹1,260 per share.

What Happened ?

Zydus Lifesciences has issued the Letter of Offer for its approved share buyback program. Under the offer, the company will repurchase up to 87.30 lakh fully paid-up equity shares from eligible shareholders through the tender offer mechanism. The buyback consideration will be paid entirely in cash and the transaction is being funded from permitted internal sources including free reserves and securities premium account.

Key Details

Buyback Structure and Shareholder Participation:

Buyback approved by the Board on May 19, 2026.
Buyback price fixed at ₹1,260 per share.
Aggregate buyback consideration capped at ₹1,100 crore.
Buyback represents approximately 0.87% of the total paid-up equity share capital.
Record date fixed as May 29, 2026.
Buyback opens on June 4, 2026 and closes on June 10, 2026.
Small shareholders will receive a reserved allocation under SEBI Buyback Regulations.
Consideration will be paid entirely in cash.
Company has confirmed that borrowed funds will not be used for the buyback.
Purchased shares will be extinguished after completion of the process.

Note:

The buyback is being undertaken through the tender offer route, allowing both retail and non-retail shareholders to participate based on their entitlement and acceptance ratio.

Risk Analysis

Summary:

While buybacks generally support shareholder returns, the final benefit to individual investors depends on acceptance ratios, oversubscription levels, and actual participation across shareholder categories.

Key Risks:

Acceptance ratio may vary depending on shareholder participation.
Shareholders tendering above entitlement are not guaranteed full acceptance.
Market price may fluctuate during the offer period.
Unaccepted shares will continue to be exposed to market movements.
Participation is subject to procedural and regulatory compliance requirements.

Worst Case Scenario:

Investors may experience lower-than-expected acceptance of tendered shares, reducing realized gains from the buyback despite participating in the offer.

Risk Level: Low

Company Commentary

The buyback has been approved in accordance with applicable provisions of the Companies Act and SEBI Buyback Regulations.
The company has confirmed adequate financial resources to execute the buyback.
The Board has stated that the company will remain capable of meeting all liabilities and obligations after completion of the buyback.
The company has confirmed that no borrowed funds will be utilized for the transaction.
The Board believes the company will continue to maintain financial strength and solvency following the buyback.

Official Exchange Filing: Zydus Lifesciences Limited